Cell & Gene Exchange, May 2017: Universal Cells, Inc.

June 16, 2017

Universal Cells is a Seattle-based biotechnology company creating therapies using gene-modified pluripotent stem cells. By editing the genome of stem cells, the company can overcome the biggest challenge—rejection—associated with cellular therapies. By overcoming rejection, we enable allogeneic therapies, avoiding the complex logistics and high cost of goods of autologous therapies. The company has created Universal Donor Pluripotent Stem Cells which:

• Can be used without donor/recipient matching

• Can be expanded indefinitely

• Retain their ability to differentiate into multiple therapeutic cell types

• Can be rigorously tested to the highest possible quality standards.

Speaker: Bryan Steadman – Chief Technology Officer

Previous Video
Cell & Gene Exchange, May 2017: Be The Match BioTherapies
Cell & Gene Exchange, May 2017: Be The Match BioTherapies

Be The Match BioTherapies partners with organizations pursuing new life-saving treatments in cellular thera...

Next Video
ChinaBio® Partnering Forum 2017: HitGen aids China drug discovery with DNA library
ChinaBio® Partnering Forum 2017: HitGen aids China drug discovery with DNA library

Wei Chen, head of R&D for Chengdu-based HitGen describes to Scrip’s Brian Yang how the Chinese startup part...